Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Miscellaneous

This is an open-label, dose-escalation Phase 1 / 2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.
Miscellaneous
I/II
Zic, John
NCT02503423
VICCDERM19130

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

Dermatologic

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or S├ęzary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing. Funding Source - FDA OOPD
Dermatologic
III
Zic, John
NCT02811783
VICCDERM1798

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: